Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells

This publication has 30 references indexed in Scilit:

• P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
  Leukemia, 2000
• The relative importance of passive and P‐glycoprotein mediated anthracycline efflux from multidrug‐resistant cells
  European Journal of Biochemistry, 2000
• Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice
  Progress in Nucleic Acid Research and Molecular Biology, 2000
• Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1999
• A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
  Biochemical Pharmacology, 1999
• Eukaryotic DNA topoisomerase IIβ
  BioEssays, 1998
• Clinical applications of anticancer drugs targeted to topoisomerase II
  Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1998
• A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia
  British Journal of Haematology, 1998
• The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy
  Leukemia, 1997
• Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
  Blood, 1991